| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Analytical Support for Drug Manufacturing in the United States’From Active Pharmaceutical Ingredient Synthesis to Drug Product Shelf Life
|
Velagaleti, Ranga
|
|
|
37 |
4 |
p. 407-438
|
artikel
|
| 2 |
A Tribute to Dr. Louis C. Lasagna: 1923–2003
|
Kaitin, Kenneth I.
|
|
|
37 |
4 |
p. 353-354
|
artikel
|
| 3 |
Erratum to: An Example of an Unblinded, Third-Party Interim Analysis for Sample Size Re-estimation
|
Kirby, Simon
|
|
|
37 |
4 |
p. 438
|
artikel
|
| 4 |
Evaluation of Wyeth Medical Communications Written Responses and the Impact on Prescribing
|
Santhouse, Arlene
|
|
|
37 |
4 |
p. 445-450
|
artikel
|
| 5 |
Impact of the ICH E9 Guideline Statistical Principles for Clinical Trials on the Conduct of Clinical Trials in Japan
|
Hirotsu, Chihiro
|
|
|
37 |
4 |
p. 381-395
|
artikel
|
| 6 |
Legal and Scientific Considerations in Nonclinical Assessment of Biotechnology Products
|
Tsang, Lincoln
|
|
|
37 |
4 |
p. 397-406
|
artikel
|
| 7 |
The Current Environment in Orphan Drug Development
|
Haffner, Marlene E.
|
|
|
37 |
4 |
p. 373-379
|
artikel
|
| 8 |
The European Regulatory Issues on Quality of Life Assessment Group Guidance: Some Critical Comments
|
,
|
|
|
37 |
4 |
p. 355-356
|
artikel
|
| 9 |
The Evolving Role of United States Industry-Based Drug Information Departments
|
Curran, Charles F.
|
|
|
37 |
4 |
p. 439-443
|
artikel
|
| 10 |
The New Drug Approvals of 1999, 2000, and 2001: Drug Development Trends a Decade after Passage of the Prescription Drug User Fee Act of 1992
|
Kaitin, Kenneth I.
|
|
|
37 |
4 |
p. 357-371
|
artikel
|
Tijdschrift beschrijving